Likang Life Sciences

Likang Life Sciences is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in personalized cancer immunotherapy. The company utilizes its proprietary L-NEO platform, which combines high-throughput sequencing and advanced bioinformatics to identify patient-specific neoantigens. These neoantigens are then used to develop customized mRNA-based vaccines and TCR-T cell therapies tailored to the unique genetic profile of an individual's tumor. Its lead candidate, LK101, is a personalized neoantigen mRNA vaccine and was the first of its kind to receive IND approval from the NMPA in China. Likang maintains an integrated business model that encompasses discovery, clinical development, and in-house GMP manufacturing. The company is backed by prominent venture capital firms and aims to address the unmet needs of patients with advanced solid tumors.